Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.10 +0.02 (0.49%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Arena Investors Need To Watch Contrave Launch Closely
Arena Pharmaceuticals (NASDAQ:ARNA) investors now have something else to pay attention to. Orexigen ... Eisai may need to at some point, but I expect the company to be conservative and to collect some data before jumping to a rash conclusion.
4 High-Gross Margin Stocks: Arena Pharmaceuticals, Inc. (ARNA), Gastar ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has return on equity ratio of -54.10%. The company has $881.56 million in market worth.
Related articles »  
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »  
Pfizer Setback Could Help Arena
Yesterday, big pharma giant Pfizer (NYSE:PFE) received news from the FDA that a panel has taken the stance of recommending that a "black box" warning remain attached to the smoking cessation drug Chantix.
Related articles »  
Hot Biotech Round Up: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that facts from the stage 3 scientific test program for BELVIQ (lorcaserin HCl) CIV will be launched at the American College of Clinical Pharmacy (ACCP) yearly conference held on last ...
Investor's Alert: Arena Pharmaceuticals, Inc. (ARNA), FuelCell Energy ...  Techsonian (press release)
Related articles »  
Belviq Sales Dip: What To Watch For Ahead
Sales of the Arena Pharmaceuticals (NASDAQ:ARNA) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress.
Hot Stocks Alert: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Sunesis ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) announced that data from the Phase 3 clinical trial program for BELVIQ (lorcaserin HCl) CIV was scheduled to be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place ...
Stocks Trending Alert-CEL-SCI (NYSEMKT:CVM), Arena Pharmaceuticals ...  Techsonian (press release)
Related articles »  
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »